Formulation Development
Vandria Announces First Subjects Dosed in First-in-Human Phase 1 Trial of VNA-318 Brain-Penetrant Mitophagy Inducer
Vandria SA recently announced the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout…
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma
Coherus BioSciences, Inc. recently announced an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and…
Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
Polyrizon Ltd. announced it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading European-based Good Manufacturing Practice (GMP) manufacturer. This collaboration will…
Silo Pharma Initiates Pharmacokinetic & Tolerability Study for SP-26 Targeting Chronic Pain & Fibromyalgia
Silo Pharma, Inc. recently announced the initiation of a pharmacokinetic (PK) and tolerability study in partnership with its contract research organization (CRO), AmplifyBio. The study…
SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the company’s second-generation…
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Channel Therapeutics Corporation recently announced it achieved its endpoints in two pre-clinical in vivo models of its nerve block formulations for acute pain, showing material…
Safi Biotherapeutics Granted Rare Pediatric Disease Designation & Orphan Drug Designation
Safi Biotherapeutics recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to their manufactured red blood cells…
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation From FDA for its Investigational Gene Therapy for Patients With Retinal Dystrophy Due to PDE6b Gene Mutations
eyeDNA Therapeutics recently announced that it has been granted a Rare Pediatric Disease Designation (RPDD) by the US FDA for HORA-PDE6b, its novel gene therapy…
Silexion Therapeutics Collaborates With Evonik on Advanced siRNA Formulation Development
Silexion Therapeutics Corp. recently announced its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed…
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE Clinical Trial
Eton Pharmaceuticals, Inc. announced the full readout and compelling results from the clinical trial evaluating PKU GOLIKE as a protein substitute for the treatment of…
GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar
GlycoNex, Inc. recently announced the first patient has been dosed in the Phase 3 clinical trial of its denosumab biosimilar, SPD8. This marks the initiation…
Immutep Announces Initial Safety Data From First-in-Human Phase 1 Trial Evaluating IMP761
Immutep Limited recently announced favorable initial safety data from the placebo-controlled, double-blind first-in-human Phase 1 study evaluating IMP761. Through the first three of five single…
Palvella Therapeutics Announces Closing of Merger With Pieris Pharmaceuticals & Concurrent Private Placement of $78.9 Million
Palvella Therapeutics, Inc. recently announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name…
Verge Genomics Announces New Development Candidate, a Novel Maintenance Therapy for Long-Term Weight Management
Verge Genomics recently announced the nomination of a second development candidate, VRG201, targeting long-term weight management and metabolic homeostasis. VRG201 is an oral, first-in-class therapy…
Atsena Therapeutics Announces Dosing Completed in Part A of Phase 1/2 Clinical Trial Evaluating Gene Therapy to Treat X-linked Retinoschisis
Atsena Therapeutics recently announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase 1/2 clinical trial evaluating subretinal injection of ATSN-201…
HUTCHMED to Receive Milestone Payment From Takeda
HUTCHMED recently announced it will receive a $10-million milestone payment by its partner Takeda. Takeda received a national reimbursement recommendation for FRUZAQLA (fruquintinib) for patients…
Assertio Announces Results of Rolvedon Injection Same-Day Dosing Clinical Study
Assertio Holdings, Inc. recently announced results of a clinical trial investigating the utility of Rolvedon (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for…
VelaLabs Announces Strategic Partnership to Support Biological Drugs Development
VelaLabs GmbH has signed a Memorandum of Understanding (MoU) with EarlyHealth Group to establish comprehensive solutions for the development of advanced biological drugs. Under the…
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use AI & Cybernetics
Conduit Pharmaceuticals Inc. recently announced it has entered into an agreement with SARBORG Limited to leverage an advanced artificial intelligence (AI) and cybernetics platform to…
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Immuneering Corporation recently announced the US FDA has granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable…
